InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
| IFRX Stock | USD 2.34 0.03 1.27% |
Slightly above 60% of InflaRx NV's investor base is looking to short. The analysis of the overall investor sentiment regarding InflaRx NV suggests that many traders are alarmed. InflaRx NV's investing sentiment can be driven by a variety of factors including economic data, InflaRx NV's earnings reports, geopolitical events, and overall market trends.
InflaRx |
Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum initiated and first patient dosed in the U.S.PG is...
Read at globenewswire.com
 |
InflaRx NV Fundamental Analysis
We analyze InflaRx NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InflaRx NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InflaRx NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
InflaRx NV is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
InflaRx NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with InflaRx NV stock to make a market-neutral strategy. Peer analysis of InflaRx NV could also be used in its relative valuation, which is a method of valuing InflaRx NV by comparing valuation metrics with similar companies.
Peers
InflaRx NV Related Equities
| INZY | Inozyme Pharma | 6.82 | ||||
| HOWL | Werewolf Therapeutics | 5.88 | ||||
| IKNA | Ikena Oncology | 2.74 | ||||
| SLS | Sellas Life | 2.02 | ||||
| FULC | Fulcrum Therapeutics | 1.22 | ||||
| RVPH | Reviva Pharmaceuticals | 1.06 | ||||
| ELDN | Eledon Pharmaceuticals | 0.95 | ||||
| GLUE | Monte Rosa | 0.36 | ||||
| STOK | Stoke Therapeutics | 0.19 | ||||
| EWTX | Edgewise Therapeutics | 0.52 | ||||
| ABOS | Acumen Pharmaceuticals | 1.14 | ||||
| PASG | Passage Bio | 1.61 | ||||
| ERAS | Erasca | 2.01 | ||||
| KZR | Kezar Life | 2.03 | ||||
| GBIO | Generation Bio | 2.08 | ||||
| PLX | Protalix Biotherapeutics | 2.77 | ||||
| KRON | Kronos Bio | 2.80 | ||||
| DSGN | Design Therapeutics | 2.93 | ||||
| CCCC | C4 Therapeutics | 2.94 | ||||
| EYPT | Eyepoint Pharmaceuticals | 3.29 |
Additional Tools for InflaRx Stock Analysis
When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.